Alkem Laboratories Limited announced on July 1, 2026, that it has received favorable Orders-in-Appeal from the Commissioner of Income Tax, Appeals – 47, Mumbai, for Assessment Years 2018-19 to 2022-23. The company made this disclosure under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, in a filing to BSE Limited and the National Stock Exchange of India.
The orders, received on June 30, 2026, delete the disallowances made under Section 80-IE of the Income-tax Act, 1961. The total tax amount involved in these disallowances is Rs 660.77 crore, which had been contested in the appellate proceedings.
Prior to these orders, the Assessing Officer had disallowed part of the deduction claimed under Section 80-IE in re-assessment orders for each assessment year from 2018-19 to 2022-23. These re-assessment orders were passed under Sections 143(3)/144 read with Section 147 of the Act, leading to the appeals.
Alkem Laboratories Limited filed the disclosure with BSE Limited, having Scrip Code 539523, and with the National Stock Exchange of India, under Scrip Symbol ALKEM, on the same date. The disclosure includes details as required under the SEBI LODR Regulations, including the nature of the action taken and the impact assessment.
The company confirmed that there is no material impact on its financial, operational, or other activities due to these favorable appellate orders. The disclosure was authorized by Manish Narang, President – Legal, Company Secretary & Compliance Officer of Alkem Laboratories Limited.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.